EHA 2015 | A review of the treatment evolution in relapsed/refractory multiple myeloma

Paul Richardson

Paul Richardson, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses his highlights of the 20th Congress of the European Hematology Association (EHA). A substantial number of new agents, including monoclonal antibodies, and emerging drug classes in clinical development have shown promising activity for the treatment of multiple myeloma.

Share this video  
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
Antibodies, Daratumumab, Elotuzumab
EHA 2015
12th June 2015
More from Paul Richardson
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
Breakthrough in relapsed multiple myeloma with PANORAMA 1 study
Recent drug approvals for the treatment of relapsed/refractory multiple myeloma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals